You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
Attention Score in Context
Title |
Phase III Trial of Gemcitabine Plus Carboplatin Versus Single-Agent Gemcitabine in the Treatment of Locally Advanced or Metastatic Non–Small-Cell Lung Cancer: The Swedish Lung Cancer Study Group
|
---|---|
Published in |
Journal of Clinical Oncology, November 2005
|
DOI | 10.1200/jco.2005.01.2781 |
Pubmed ID | |
Authors |
Christer Sederholm, Gunnar Hillerdal, Kristina Lamberg, Karl Kölbeck, Monika Dufmats, Ronny Westberg, Sulochana R. Gawande |
Abstract |
This phase III study compared overall survival in patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) when treated with single-agent gemcitabine versus gemcitabine/carboplatin. Secondary objectives were to compare response, time to progression, toxicity, and quality of life. |
Mendeley readers
The data shown below were compiled from readership statistics for 83 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
Brazil | 2 | 2% |
United Kingdom | 1 | 1% |
Australia | 1 | 1% |
Spain | 1 | 1% |
Unknown | 78 | 94% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 15 | 18% |
Other | 14 | 17% |
Student > Ph. D. Student | 12 | 14% |
Student > Master | 10 | 12% |
Lecturer | 5 | 6% |
Other | 15 | 18% |
Unknown | 12 | 14% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 47 | 57% |
Agricultural and Biological Sciences | 6 | 7% |
Nursing and Health Professions | 4 | 5% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 2% |
Social Sciences | 2 | 2% |
Other | 5 | 6% |
Unknown | 17 | 20% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 June 2006.
All research outputs
#15,233,109
of 22,649,029 outputs
Outputs from Journal of Clinical Oncology
#16,656
of 19,837 outputs
Outputs of similar age
#123,230
of 145,675 outputs
Outputs of similar age from Journal of Clinical Oncology
#161
of 176 outputs
Altmetric has tracked 22,649,029 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 19,837 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 19.2. This one is in the 9th percentile – i.e., 9% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 145,675 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 5th percentile – i.e., 5% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 176 others from the same source and published within six weeks on either side of this one. This one is in the 2nd percentile – i.e., 2% of its contemporaries scored the same or lower than it.